Nitric oxide is a naturally occurring molecule known to have antimicrobial properties, including a direct effect on SARS-CoV-2 and its variants, the virus that causes COVID-19.
The new study, conducted at Srinakharinwirot University in Bangkok, Thailand, found participants who took NONS after COVID-19 exposure were 75% less likely to become infected when compared to the control group, yielding a statistically significant reduction in infection rate.
The study was carried out during an emergency effort by the University to contain an Omicron outbreak in February, 2022. Medical personnel, students, and professors (1,039 individuals, aged 18-60) were quarantined in dormitories after possible COVID-19 exposure.
Individuals were included in the current analysis if they had confirmed high-risk exposure to a COVID-19 infected roommate (defined as being within one to two meters of the infected individual for at least five minutes without a mask). NONS was offered to staff and students who reported exposure.
After exclusion for being low-risk or testing positive via antigen test kit within 24 hours, 625 student participants were included in the analysis. Of these, 203 participants used NONS at least four times per day and 422 volunteers did not use NONS.
All volunteers were tested via ATK on the fifth, seventh, and tenth day of quarantine, and positive tests were confirmed by PCR.
Among the 203 participants who used NONS, 13 tested positive (6.4% infection rate). Of the 422 in the control group, 108 participants tested positive (25.6% infection rate), a statistically significant difference from the treatment group (P
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study
Precision Epigenomics partners with TruDiagnostic
Modalis partners with Ginkgo Bioworks
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Algiax Pharmaceuticals reveals update on chronic neuropathic pain study